Annette Clancy

Annette Clancy has extensive experience in the life sciences and healthcare sectors, holding significant leadership roles across multiple organizations. Currently serving as an Operational Investor at JEITO since January 2020 and Chairperson of the Board at Sobi since January 2024, Clancy previously held the position of Non Executive Director at Sobi from May 2014 to January 2024. Additionally, Clancy chaired the Board of Directors at ENYO Pharma until December 2023 and led Obseva Ltd as Chair of the Board and Non Executive Director until March 2023. Clancy also served as a Senior Advisor at Frazier Healthcare Ventures from 2009 to December 2017 and was the Chairman of the Board at Genable Technologies Limited from January 2013 to March 2016, where a successful sale to Spark Therapeutics took place. Clancy’s career began at GlaxoSmithKline, where leadership in worldwide business development as Head of Transactions and Alliance Management spanned three decades, from 1978 to 2008.